Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide

Completed

• Conditions: Hypertension
• Interventions: Drug: Telmisartan and hydrochlorothiazide

• Registration Number: NCT02248129
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Study to compare the level of blood pressure control in hypertensive, hypertensive diabetics and hypertensive with renal insufficiency (observed data) in the study population, with the objectives of the High Authority for Health recommendations (benchmark)

Detailed Description

Not available

Study Timeline

• Study Start: 2006-04
• Primary Completion: 2006-12
• Status Verified: 2014-09
• Study First Submitted: 2014-09-22
• Study First Submitted QC: 2014-09-22
• Last Update Submitted: 2014-09-22
• Study First Posted: 2014-09-25
• Last Update Posted: 2014-09-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4255

Inclusion Criteria

• Hypertensive patients already treated for at least 1 month with Telmisartan plus hydrochlorothiazide, consulting the physician consecutively for whatever reason

Read More

Exclusion Criteria

• NA

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Hypertensive patients	Telmisartan and hydrochlorothiazide	-

Primary Outcome Measures

Name	Time	Method
Percentage of patients with low blood pressure	up to 4 weeks	lower than 140/90 mmHg in the general population of hypertensive patients, hypertensive diabetics and hypertensive with renal insufficiency

Secondary Outcome Measures

Name	Time	Method
Number of patients with adverse events	up to 4 weeks